UAFRS vs As Reported Monthly Newsletter - 2020 01 31
This month, Valens identified distortions and the corresponding adjustments to correct for those distortions for AMAG, PTC, AEGN, HQY, NBIX, and MAR.Aegion is a holding company. The company is engaged in providing solutions to rehabilitate aging infrastructure, primarily pipelines in the wastewater, water, energy, mining and refining industries. The company also maintains the operation of refineries and other industrial facilities. The company's segments are: Infrastructure Solutions, which include Insituform? cured-in-place pipe, the Tyfo? system and Fusible polyvinyl chloride? pipe product brands; Corrosion Protection, which is positioned to capture the benefits of continued oil and natural gas pipeline infrastructure developments; and Energy Services, which provides safety and labor productivity programs.
AMAG Pharmaceuticals is a pharmaceutical company focused on bringing products to patients in the areas of maternal and women's health, anemia management and cancer supportive care, including Feraheme? (ferumoxytol injection) for intravenous use, Makena? (hydroxyprogesterone caproate injection), Intrarosa? (prasterone) vaginal inserts and MuGard? Mucoadhesive Oral Wound Rinse. The company's portfolio also includes three product candidates, Vyleesi? (bremelanotide), which is for the treatment of hypoactive sexual desire disorder in pre-menopausal women, AMAG-423 (digoxin immune fab (ovine)), which is for the treatment of preeclampsia, and ciraparantag, which serves as an anticoagulant reversal agent.
HealthEquity provides technology-enabled services platforms that enable consumers to make healthcare saving and spending decisions. The company's platform provides an ecosystem where consumers can access their tax-advantaged healthcare savings, compare treatment options and pricing, evaluate and pay healthcare bills, receive personalized benefit and clinical information, earn wellness incentives, and make educated investment choices to grow their tax-advantaged healthcare savings. The company's products and services include healthcare saving and spending platform; health savings accounts; investment platform and advisory services, reimbursement arrangements; and HealthEquity retirement.
Marriott International is a worldwide operator, franchisor, and licensor of hotel, residential and timeshare properties under various brand names at different price and service points. The company has operations in the following reportable business segments: North American Full-Service, which includes the company's Luxury and Premium properties located in United States and Canada; North American Limited-Service, which includes the company's Select properties located in United States and Canada; and Asia Pacific, which includes all properties in the company's Asia Pacific region.
Neurocrine Biosciences is a commercial-stage biopharmaceutical company focused on discovering and developing treatments for patients with neurological, endocrine and psychiatric disorders. The company is primarily focused on the commercialization of INGREZZA? (valbenazine) in the United States. The company's late-stage pipeline includes opicapone as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients, elagolix for the treatment of heavy menstrual bleeding associated with uterine fibroids in women, valbenazine for the treatment of chorea in adult patients with Huntington's disease and NBIb-1817 (VY-AADC) for the treatment of Parkinson's disease patients.
PTC is a software and services company. The company's products and services include: 3D Modeling, which enables users to create designs, analyze designs, perform engineering calculations and utilize the information created downstream using 2D, 3D, parametric and direct modeling; Lifecycle Management, which enables product data management, as well as communication and collaboration across the enterprise, including product development, manufacturing and the supply chain; Data Orchestration, which delivers tools, technologies, and solutions that enable companies to develop and deploy industrial IoT applications; and Experience Creation, which provides a way to capture, create, and deliver content.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
- GAAP and IFRS have failed to provide rules for reliable financial statement reporting
- Stock analyst recommendations are not grounded in disciplined financial analysis
- Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
- Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
- Corporate credit ratings remain years behind the fundamental underpinnings of company performance
- Stock analysts continue to make recommendations with deeply inherent biases
- Research firms have failed to break down the walls between credit, equity, and macroeconomic research
- The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.